14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today BPTH ranks #13674 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

$5.04 (-3.82%)

Volume: 86k

Closed: Oct 22, 2021

Hollow Logo Score: -3.000

Bio-Path Holdings Stock Forecast

$5.04 (-3.82%)

Volume: 86k

Closed: Oct 22, 2021

Score Hollow Logo -3.000

Bio-Path Holdings Company Profile

4710 Bellaire Boulevard

Bellaire TX 77401



Bio-Path Holdings


Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is Liposomal Grb2, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. The company was founded in 2007 and is based in Bellaire, Texas.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE